NICE (NASDAQ:NICE) reported quarterly earnings of $1.92 per share which beat the analyst consensus estimate of $1.87 by 2.67 percent. This is a 14.29 percent increase over earnings of $1.68 per share from the same period last year. The company reported quarterly sales of $554.70 million which beat the analyst consensus estimate of $548.81 million by 1.07 percent. This is a 12.19 percent increase over sales of $494.41 million the same period last year.
Needham Reiterates Buy on Cara Therapeutics, Maintains $26 Price Target
Needham analyst Joseph Stringer reiterates Cara Therapeutics (NASDAQ:CARA) with a Buy and maintains $26 price target.